PURPOSECannabis has been legalized across multiple states over the past decade; however, its use among cancer survivors ...

Under-reporting of treatment-related adverse events is commonplace in cancer drug trials, which are often accompanied by terms that downplay the seriousness of these events. 1 - 3 Cardiovascular ...

Artificial Intelligence–Based Digital Histologic Classifier for Prostate Cancer Risk Stratification: Independent Blinded Validation in Patients Treated With Radical Prostatectomy ...

PURPOSEFinancial barriers remain a critical issue for adolescent and young adults (AYAs, 18-39 years) with cancer, who face unique challenges because of their life stage and transitional care needs.

PURPOSEHematologic malignancies (HMs) account for 4%-10% of cancers in individuals with Li-Fraumeni syndrome (LFS), but their phenotypic spectrum and clinical outcomes remain incompletely ...

JCO invites you to enter our first Art of Oncology Narrative Medicine Contest for early career oncologists. Entries will be accepted through August 31, 2025. Finalists will be judged by a panel of ...

Pharmacologic suppression of graft-versus-host disease (GVHD) is critical to the success of hematopoietic stem cell transplantation (HSCT). 1 The use of cyclophosphamide for GVHD prevention has ...

Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial The following represents ...

Patients with pretreated R/M CC were randomly assigned to receive camrelizumab (200 mg intravenously once every 3 weeks) plus famitinib (20 mg orally once daily), camrelizumab, or investigator's ...

PURPOSEWe conducted a randomized controlled trial (SURF-RCT) to evaluate the efficacy of surgery versus radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Simultaneously, eligible ...

Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. We report a subset analysis of older patients (60 years and older) enrolled in the phase three ...

In the article that accompanies this editorial, Babiker et al 12 present the data that tumor-treating fields (TTFs) combined with gemcitabine plus nab-paclitaxel improved median overall survival ...